Review time of oncology drugs and its underlying factors: an exploration in China
Introduction: How the launch delay of drugs and other factors of interest can influence the length of the review period by drug agencies is still unknown, and understanding this can help better strike the trade-off related to review speed.Methods: We included all new oncology drug applications submi...
Main Authors: | Xingyue Zhu, Bao Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1151784/full |
Similar Items
-
Impact of Oncology Drug Review Times on Public Funding Recommendations
by: Marya Hussain, et al.
Published: (2023-08-01) -
Assessment of the implementation of accelerated drug marketing registration procedures for antineoplastic and immunomodulating agents in China: based on 2016–2022 review data
by: Yipeng Lan, et al.
Published: (2024-03-01) -
International oncology drug approvals for multiregional or single-country clinical trials: A systematic review
by: Min Zhang, et al.
Published: (2022-12-01) -
Bridging the new drug access gap between China and the United States and its related policies
by: Xingyue Zhu, et al.
Published: (2024-01-01) -
Drugs approved by CDSCO, India in 2015
by: K Parushuram Naik1 , V Sai Lakshmi2 , J Jyothirmai3
Published: (2016-04-01)